The company has market cap of $127.54 million. The firm provides various machines that enable designers and engineers to design and produce industrial prototypes and production parts. It now has negative earnings.
Recent insider trends for Advaxis, Inc. (NASDAQ:ADXS) is a huge mover today! A total of 1.27 Million shares exchanged hands, whereas the company's average trading volume stands at 576.75 Million shares.
Media headlines about Advaxis (NASDAQ:ADXS) have been trending somewhat positive on Monday, Accern reports. It has underperformed by 5.69% the S&P500.The move comes after 5 months negative chart setup for the $121.85 million company. It was reported on Jan, 28 by Barchart.com. The recent change has given its price a 4.82% lead over SMA 50 and -68.39% deficit over its 52-week high.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials created to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma. Sold All: 12 Reduced: 18 Increased: 20 New Position: 17. (NASDAQ:ADXS). Balyasny Asset Management Llc accumulated 21,417 shares. Vident Invest Advisory Ltd invested 0.04% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) by some 1,815,049 shares, 32 decreased positions by 3,789,868 and 33 held positions by 12,125,915. Guggenheim initiated Advaxis, Inc. (ADXS)'s shares. The total value of these holdings, in millions, is $52. Sarissa Capital Management Lp owns 339,180 shares or 0.44% of their USA portfolio. Sabby Limited Liability Corporation invested in 37,634 shares. (NASDAQ:ADXS) on Friday, September 11 with "Buy" rating.
Advaxis Inc Cmn Stk (NASDAQ:ADXS)'s distance from 20 day simple moving average is -0.0155 along with distance from 50 day simple moving average of 3.03 whereas its distance from 200 day simple moving average is 4.46.
Several research analysts have recently issued reports on the stock. Barclays Capital initiated the shares of ADXS in report on Tuesday, September 22 with "Overweight" rating. ADXS was included in 8 notes of analysts from September 11, 2015. The company was maintained on Thursday, July 6 by Cantor Fitzgerald. (NASDAQ:ADXS) rating on Wednesday, May 31. Cantor Fitzgerald has "Buy" rating and $1900 target. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. On Wednesday, June 14 the stock rating was maintained by H.C. Wainwright with "Buy". (NASDAQ:ADXS) has "Buy" rating given on Wednesday, June 14 by H.C. Wainwright. The firm earned "Buy" rating on Wednesday, November 8 by H.C. Wainwright. In a transaction dated November 06, 2017, the shares were put up for sale at an average price of $3.3, raking in a sum of $12,286.
Since January 1, 0001, it had 0 buys, and 2 insider sales for $200,347 activity. The company now has a Return on Equity of -114% and a Return on Investment of -173.3%. The stock has a market capitalization of $119.5 Million however its outstanding shares are 40.51 Million. Fabrinet (NYSE:FN) has a Return on Assets (ROA) of 0. A value between 0 to -20 would represent a strong overbought condition. Capstone Investment Advisors Llc, a New York-based fund reported 20,000 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.